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Objectives: To investigate the association of state-level Medicaid expansion and nonelderly mortality rates from 1999 to 2018 in Northeastern urban settings.
Methods: This quasi-experimental study utilized a synthetic control method to assess
the association of Medicaid expansion on non-elderly urban mortality rates [1999–2018].
Counties encompassing the largest cities in the Northeastern Megalopolis (Washington
D.C., Baltimore, Philadelphia, New York City, and Boston) were selected as treatment
units (n = 5 cities, 3,543,302 individuals in 2018). Cities in states without Medicaid
expansion were utilized as control units (n = 17 cities, 12,713,768 individuals in 2018).

Edited by:
Steven W. Howard,
Saint Louis University, United States
Reviewed by:
Rebecca Thorsness,
Brown University, United States
Alyssa Coleman,
Saint Louis University, United States
*Correspondence:
Cyrus Ayubcha
cyrusayubcha@hms.harvard.edu
Specialty section:
This article was submitted to
Public Health Policy,
a section of the journal
Frontiers in Public Health
Received: 05 October 2021
Accepted: 08 October 2021
Published: 17 November 2021
Citation:
Ayubcha C, Pouladvand P and
Ayubcha S (2021) A
Quasi-Experimental Study of Medicaid
Expansion and Urban Mortality in the
American Northeast.
Front. Public Health 9:707907.
doi: 10.3389/fpubh.2021.707907

Results: Across all cities, there was a significant reduction in the neoplasm
(Population-Adjusted Average Treatment Effect = −1.37 [95% CI −2.73, −0.42]) and
all-cause (Population-Adjusted Average Treatment Effect = −2.57 [95%CI −8.46,
−0.58]) mortality rate. Washington D.C. encountered the largest reductions in mortality
(Average Treatment Effect on All-Cause Medical Mortality = −5.40 monthly deaths per
100,000 individuals [95% CI −12.50, −3.34], −18.84% [95% CI −43.64%, −11.67%]
reduction, p = <0.001; Average Treatment Effect on Neoplasm Mortality = −1.95
monthly deaths per 100,000 individuals [95% CI −3.04, −0.98], −21.88% [95% CI
−34.10%, −10.99%] reduction, p = 0.002). Reductions in all-cause medical mortality
and neoplasm mortality rates were similarly observed in other cities.
Conclusion: Significant reductions in urban mortality rates were associated with
Medicaid expansion. Our study suggests that Medicaid expansion saved lives in the
observed urban settings.
Keywords: Medicaid expansion, Medicaid, cities, mortality, urban

INTRODUCTION
The Affordable Care Act (ACA) offered states the opportunity to expand health insurance coverage
to non-elderly adult populations through Medicaid expansion (ME). States were able to use federal
funding to increase state Medicaid coverage to all those US Citizens and permanent residents
with incomes at or below 138% federal poverty level (FPL) (1). Specific narrow categories of
eligibility (e.g., impoverished pregnant women) were federally mandated earlier. Prior to the 2014
implementation of ACA Medicaid expansion, some states utilized waivers to preemptively expand
their programs sometimes with more expansive eligibility criteria, but significant gaps in coverage
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environmental factors that underlie treatment effects. Our study
does not only examine all-cause medical mortality but also
certain cause-specific mortality rates (e.g., circulatory mortality,
neoplasm mortality, etc.). This study will help to understand
whether expanding medical coverage can reduce all-cause and
cause-specific urban mortality rates, thus helping illuminate why
health coverage may improve health for some but not all.

persisted (2). As a result of Medicaid expansion, Medicaid
take-up increased in less-educated, low-income, minority, and
younger adults residing in expansion states as compared to peers
in nonexpanded states (3). What remains unclear is whether
this increase in coverage improved health outcomes, particularly
whether urban settings observed reductions in mortality.
Cost-benefit considerations, entailing monetary cost, value
of increasing coverage, and the quality of care provided to
beneficiaries, have been of notable interest in the debate to
increase public medical coverage (4). The original Medicaid
program has been associated with moderate decreases in
mortality depending on the methods employed (5). Expansions
of Medicaid to pregnant women and children during the 1980s
were linked to decreases in infant mortality and maternal
mortality in most studies (6, 7). Analyses of the 2006
Massachusetts Health Care Reform (MHCR) found reduced
all-cause mortality by nearly 8.2 deaths per 100,000 adults
(8–10). However, the Oregon Healthcare Experiment study
suggested that the effects of coverage may not be immediate
or large (11). Such variability may suggest the mechanisms and
impact of health coverage is contingent upon alternative factors
(e.g., urban-rural residence, minority identity, socioeconomic
status, etc.); specific benefits to certain sub-populations or
temporally removed effects may further underlie such variability.
Smaller mortality effects may also be challenging to capture
as gains in public insurance can often be centered in younger
populations though older populations are most likely to benefit
from coverage.
A number of studies have examined the ACA Medicaid
expansion directly and these studies also gesture toward
effect heterogeneity in increasing coverage. Nationwide studies
observed a decline in all-cause mortality following the ACA
Medicaid expansions, but not in cause-specific mortality rates
(cardiovascular, respiratory, suicide, and opioid overdose) (12)
while a separate analysis found only small, insignificant effects
(13). Emerging evidence suggests that Medicaid expansion may
have reduced excessive mortality for minorities, in part, by
reducing amenable mortality (10, 14). These reforms also seem
to have reduced maternal mortality rates, particularly for latematernal deaths and Black mothers (15, 16). Some studies have
observed improvements in specific mortality measures, such as
cardiovascular mortality in near-elderly populations and oneyear mortality rates among end-stage renal disease patients (17,
18).
We examine the influence of Medicaid expansion on the
mortality rates in various Northeastern urban centers. Urban
populations warrant targeted study as they are largely distinct
from state-wide populations with respect to diversity, healthcare
access barriers, types of disease burden and disparities; this is not
to mention that a majority of Americans reside in urban settings
(19–24). Notably, most large American metropolitan centers are
unique in characteristics and state policy history which presents
difficulties in studying the generalized “urban” populations. This
motivates our study to take a narrow and detailed examination
into each city to determine the impact of Medicaid expansion.
Accordingly, the observed changes across the included cities
may be a means to logically deducing certain city-specific
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MATERIALS AND METHODS
Study Design and Inclusion Criteria
We utilized a quasi-experimental design to assess the mortality
rate among those aged 20–64 from 1999 to 2018; where observed
mortality rates after Medicaid expansion were compared to
respective predicted mortality rates for each treated city. Only
cities in the Northeast megalopolis were considered when
selecting treated urban counties. The first year of treatment
for each treated city unit was considered the year in which
statewide Medicaid expansion was enacted. Urban counties
within non-expansion states were selected for the control group.
All urban counties with sufficient population levels (>9,000
individuals) and population density and (>800 individuals/mi2)
were included. States and counties with any previous Federal
Poverty Level (FPL)-based waiver expansions were eliminated
from this control pool (e.g., Wisconsin, St. Louis City, MO). The
counties utilized in this study can be found in Table 1.

Data Sources
All data were secondary, public, and de-identified; no
institutional review board approval or informed consent
was required. County-level age-adjusted mortality data
for individuals between the ages of 20–64 were compiled
from the Centers for Disease Control WONDER Tool. The
following categories of mortality were included: diseases of the
circulatory system mortality (circulatory mortality), diseases
of the respiratory system mortality (respiratory mortality),
all-cause medical mortality, and neoplasm mortality (i.e., cancer,
malignancy). All-cause medical mortality was defined as allcause mortality absent external-cause mortality. Categories of
mortality were defined by International Classification of Diseases
(ICD) coding systems; the ICD 9 to ICD 10 code transition
was reconciled.
Several longitudinal county-level covariates were obtained
and utilized as the basis for developing the synthetic control for
each treatment city. From 1999 to 2018, healthcare coverage rates
were attained from the Small Area Health Insurance Estimates,
non-Hispanic white percentages of populations between 20
and 64 were calculated using the Bridged-Race Population
Estimates, inflation-adjusted median income and poverty rates
were captured in data from the Bureau of Economic Analysis
and the Small Area Income and Poverty Estimates. The
Economic Research Services of the United States Department
of Agriculture provided educational attainment fractions as
defined as the fraction of those with at least some college.
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TABLE 1 | Treatment conditions of included cities.
City

County

State

Expansion year

Expansion FPL

Treatment

Baltimore†

Baltimore City

MD

2014

138%

Treatment

San Antonio

Bexar

TX

None

None

Control

Fort Lauderdale

Broward

FL

None

None

Control

Dallas

Dallas

TX

None

None

Control

Nashville

Davidson

TN

None

None

Control

Washington D.C.††

District of Columbia

2010

210%

Treatment

Atlanta

Fulton

GA

None

None

Control

Houston

Harris

TX

None

None

Control

Kansas City

Johnson

KS

None

None

Control

Charlotte

Mecklenburg

NC

None

None

Control

Memphis

Shelby

TN

None

None

Control

Miami

Miami-Dade

FL

None

None

Control

New York City‡

New York

NY

2014

138%

Treatment

Oklahoma City

Oklahoma

OK

None

None

Control

Orlando

Orange

FL

None

None

Control

Philadelphia

Philadelphia

PA

2015

138%

Treatment

Tampa St. Petersburg Clearwater

Pinellas

FL

None

None

Control

Salt Lake City

Salt Lake

UT

None

None

Control

Boston‡‡

Suffolk

MA

2014

138%

Treatment

Fort Worth

Tarrant

TX

None

None

Control

Austin

Travis

TX

None

None

Control

Raleigh

Wake

NC

None

None

Control

†

07/01/06 § 1115 Waiver that established the Primary Adult Care program to expand coverage (prescription, primary care, behavioral health) to childless adults at or below 116%
of FPL.
††
07/01/10 State Plan Amendment extends Medicaid coverage to 133% FPL | 12/01/10 § 1115 Waiver Early ACA expansion extends Medicaid program to 210% of FPL.
‡ 10/01/01 § 1115 Waiver extends Medicaid Family Health Plus to childless adults at 100% FPL.
‡ ‡ 4/6/06 Massachusetts implemented reforms to expand insurance coverage to low- income adults beginning in 2006.

treated city; selection of weights chiefly aims to create a synthetic
city with similar pre-intervention covariate characteristics (e.g.,
inflation-adjusted median income, lagged mortality rates) to the
treated city; this algorithmic process employed by the GSC is
akin to creating a control city with similar characteristics to
the treated city. The appropriateness of the synthetic city as a
comparator to the treated city is determined by the convergence
of the pre-intervention outcome trends between the treated city
and the synthetic city. Such that, any divergence of trends in
the post-intervention can be attributed to the intervention (i.e.,
Medicaid expansion).
In this study, we utilize a Generalized Synthetic Control
(GSC) model (25) for each treated city and specific mortality
rate. The GSC model relies upon an interactive fixed effects
(IFE) technique within the synthetic control framework.
The use of IFE incorporates two-way fixed effects which
enabled our model to account for unobserved unit-specific
and time-specific confounding variables. IFE modeling
of the control units is then used to create out-of-sample
predictions for the treated unit which results in a GSC
output of the synthetic city’s mortality rates. The difference
between the synthetic and treatment mortality outcomes
is considered the treatment effect on the treated unit.
The post-intervention difference between the trends can be

Unavailable covariate data for health insurance coverage (1999–
2005) were interpolated using only the trends provided by fiveyear American Community Survey estimates and Census data.

Main Data Outcomes
Mortality was acquired from 1999 to 2018 and all rates were
calculated as age-adjusted deaths per 100,000 population of 20–
64-year-olds in the county. Monthly data were used for all-cause
medical mortality and neoplasm mortality rates, while yearly data
were used for all other forms of mortality; more granular data
(i.e., monthly as opposed to yearly) provided greater statistical
power but less common forms of mortality lacked sufficient
prevalence to justify monthly analyses in light of limited sample
sizes and elevated risk of stochasticity.

Statistical Analysis
This study employs synthetic control methods which are
advantageous when no single control unit can serve as an ideal
comparator for a treated unit. This application creates a synthetic
control city unit through a weighted combination of the control
cities. The synthetic city is intended to simulate the mortality
rate of the treated city (e.g., Philadelphia) in the post-treatment
period (e.g., 2015–2018) if Medicaid had not been expanded. The
particular weights varied in the specific model as applied to each
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averaged over the post-treatment period; termed the average
treatment effected in the treated units (ATT). Parametric
bootstrapping inference tests were applied to ascertain
uncertainty estimates (25).
One sensitivity test was performed by rerunning the models
of the monthly data in yearly format to determine whether
the structure of yearly analyses influenced the model. An intime placebo sensitivity analysis was performed applying a
false intervention point in the middle of the pre-intervention
period and running the GSC model through the pre-intervention
period; specifically, the pre-treatment period was considered
1999–2005 and the post-treatment period was considered
2006–2007 so that the 2008 economic downturn was not
included. Given that insurance rate is considered a significant
mediating variable, a secondary analysis was also performed
utilizing county-level insurance rates for each of the treatment
cities. The GSC model was applied to insurance coverage
rates as a secondary outcome using all the predictors utilized
in the main models except for mortality data. All statistical
analyses were conducted in R (version 4.0.0) using the
gsynth package.

The GSC overcomes some limitations of alternative methods.
The GSC does not rely upon the parallel trend assumption
that is required in the difference-in-differences methods (25).
The GSC method has further proven to be less sensitive to
idiosyncratic volatility with a small number of observations (25).
Furthermore, this method does not require sensitivity tests of
model specifications as a cross-validation procedure selects the
optimal number of factors in the IFE model (25). Nevertheless,
the GSC model does assume that a stable combination of control
units based on the pre-intervention period characteristics of
the treatment and control pool can approximate the outcomes
of the treated unit in the post-intervention period absent
the intervention. Such advantages may achieve similar or
superior performance as compared to other methods; several
simulated and applied health policy studies comparing IFE,
GSC, DiD, and synthetic control methods have found that
GSC models perform best (25, 26). Finally, the GSC structure
allows for robust parametric bootstrapping inference whereas
such quantitative inference is unavailable for traditional synthetic
control methods.

RESULTS
We found evidence of significant reductions in all-cause medical
mortality as compared to predicted mortality had expansion not
occurred in four cities, including Washington D.C., Baltimore,
Philadelphia, and New York, after their 2010, 2014, 2015, and
2014 expansions of Medicaid, respectively (Figures 1–5). Similar

FIGURE 1 | All-cause mortality trends: Washington D.C. and synthetic
control city. The blue dotted lines represent the generalized synthetic control
prediction (synthetic city) of mortality rates while the solid black line is the
observed mortality rate of the Medicaid expansion city. The vertical axis of the
graphs represents the per 100,000-person mortality rates. The horizontal axis
of the graphs represents time units (i.e., the first month of the year). The darker
gray graph areas correlate with the start and duration of Medicaid expansion in
the respective city (applicable for all the figures).
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FIGURE 2 | All-cause mortality trends: Baltimore and synthetic control city.
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FIGURE 3 | All-cause mortality trends: Philadelphia and synthetic control city.

FIGURE 5 | All-cause mortality trends: Boston and synthetic control city.

FIGURE 4 | All-cause mortality trends: New York and synthetic control city.

FIGURE 6 | Neoplasm mortality trends: Washington D.C. and synthetic
control city.
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FIGURE 7 | Neoplasm mortality trends: Baltimore and synthetic control city.
FIGURE 9 | Neoplasm mortality trends: New York and synthetic control city.

FIGURE 8 | Neoplasm mortality trends: Philadelphia and synthetic control city.
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FIGURE 10 | Neoplasm mortality trends: Boston and synthetic control city.
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effect sizes are seen across all cities (ATT range = −1.39 to −2.78)
apart from Washington D.C., which saw a much larger decrease
(ATT = −5.40). The −5.40 ATT value for Washington D.C.
conveys that the average monthly neoplasm mortality rate per
100,000 was reduced by 5.40 over the post-intervention period.
When assessing neoplasms, we observe a significant reduction
in mortality in four cities excluding New York (Figures 5–
10). Pooled across all cities, there was a significant reduction
in the neoplasm (Population-Adjusted ATT = −1.37 [95%
CI −2.73, −0.42]) and all-cause medical (Population-Adjusted
ATT = −2.57 [95% CI −8.46, −0.58]) mortality rates but not
cardiovascular (Population-Adjusted ATT = −3.79 [95% CI
−24.57, 11.68]) and respiratory mortality (Population-Adjusted
ATT = −0.91 [95% CI −6.99, 4.89]) (see Figures 12–22 in
the Appendix).
According to established practices, we discard models that
have grossly mismatched pre-intervention mortality trends
between the treatment and synthetic units (27); this was
only observed for respiratory mortality in Baltimore, which
was highly volatile. Subsequently, the treatment effect was
calculated through the ATT and CTT parameters; p-values
indicated levels of statistical significance (Table 2; Figure 11).
Parameters (ATT, %ATT, or CTT), time unit of measurement
(yearly or monthly), and post-intervention period length
must be considered when comparing across the reported
values. Overall, our synthetic control models indicate a trend
of decreases in neoplasm and all-cause medical mortality
rates in cities that expanded Medicaid compared to their
estimated counterfactuals. Sensitivity analyses of monthly data
converted to yearly data indicated that the analysis was
not sensitive to yearly data. Specifically, the conversion of
monthly all-cause medical and neoplasm mortality into yearly
aggregates changed significant differences into insignificant
differences (see Tables 1, 2 in the Appendix). The intime placebo sensitivity analysis indicated that the false
intervention time point did not result in significant change
in mortality rates (see Table 3 and Figures 11–20 in the
Appendix). The weighted composition of each synthetic control
model in the mortality analyses is included (see Table 4
in Appendix).
The generalized synthetic control analyses of insurance rates
indicated that the observed city after Medicaid expansion were
all much greater than predicted (Table 3) (see Figures 21–25 in
Appendix). Most notably, the gains in Washington D.C. (ATT
= 4.23%, p = 0.050), Baltimore (ATT = 3.23%, p = 0.048), and
Philadelphia (ATT = 4.30% p = 0.046) were significantly greater
than the predicted trends in the absence of Medicaid expansion.
New York and Boston, two cities with already had high rates of
coverage prior to Medicaid expansion and the derived treatment
effects did not significantly differ from the predicted gains.

ACA Medicaid expansion. Second, while Medicaid expansion
does appear to be associated with reductions in mortality rates
across the cities, we observe evidence of varied effects. Third,
analyses of yearly data in this study generally lacked sufficient
statistical power.
Most cities experienced significant decreases in neoplasm
mortality and all-cause medical mortality after Medicaid
expansion as compared to the predicted rates. The potential
mechanisms of this observed decline may be several. An intended
function of Medicaid expansion was to decrease the uninsured
rate (15, 16). While there was uptake of Medicaid coverage,
much of this enrollment was moderate followed by a mild and
steady increase (11). While the magnitude of increased insurance
coverage may appear minor, more ill and vulnerable populations
(e.g., women, African Americans, Hispanics, immigrants)
gained coverage through Medicaid expansion which may
explain the larger decrease in mortality observed in this
study (11, 28).
New enrollees encountered reduced financial barriers which
led to receiving timelier clinical and surgical care along
with better ability to access prescription medicines for acute
and chronic conditions (29–33). Improved self-reported and
objective measures of quality as a result of Medicaid expansion
accompanied increasing use of preventive care (34). In totality,
Medicaid expansion reduced financial barriers and improved
integration of communities in medical systems which resulted
in individuals receiving more necessary and high-quality medical
care (34). Additionally, Medicaid expansion has been associated
with increased overall financial stability (35, 36). Greater financial
stability, especially for those managing chronic conditions or
suffering catastrophic events, not only allows for appropriate
seeking of care but also may lead to broader health benefits. For
example, families with greater financial stability are more able
to achieve higher standards of living which act through material
and psychosocial mechanisms to produce superior wellbeing
(12, 37).
Considering neoplasm mortality, long standing research has
generally considered the inability to access quality medical care
as the major determinant of mortality especially in populations
with lower socioeconomic status (37). Numerable studies of
those with newfound access to Medicaid indicated that these
individuals benefited greatly from expansion in the context of
cancer care and mortality (38–42). As disease stage influences
neoplasm prognosis, access to care is naturally a significant
influence on neoplasm mortality (37). The longitudinal nature
of oncological disease would suggest that reductions in mortality
should become more profound as time passes from Medicaid
expansion. Nevertheless, more proximal effects on cancer
mortality due to the newfound ability to access diagnostic care
and treatment have been reproduced not only in this study
but also in others. Those with undiagnosed cancers were found
to receive earlier screenings and diagnostic tests leading to
appropriate oncological intervention (38, 42). Examining data
as early as three-years after Medicaid expansion, Lin et al.
found a reduction of late-stage lung cancer diagnoses and an
increase in early-stage lung cancer diagnoses (41). Lung cancer
as well as other aggressive forms of cancer may progress rapidly

DISCUSSION AND CONCLUSION
Three principal conclusions can be drawn from our analysis.
First, we document significant declines in all-cause medical
mortality, partly driven by concurrent and significant reductions
in neoplasm mortality, in most Northeastern cities following
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TABLE 2 | Treatment effects on mortality rates in treated cities.
ATT

Lower 95% CI

Higher 95% CI

ATT%

†

ATT% Lower 95% CI

ATT% Higher 95% CI

p

Washington D.C. | 2010
Circulatory mortality

−14.83

−45.20

7.47

−13.62

−41.51

6.86

0.168

Respiratory mortality

2.31

−6.21

9.73

18.39

−49.41

77.43

0.658

Neoplasm mortality

−1.95

−3.04

−0.98

−21.88

−34.10

−10.99

0.002***

All-cause medical mortality

−5.40

−12.50

−3.34

−18.84

−43.64

−11.67

< 0.001***

Baltimore | 2014
Circulatory mortality

−7.00

−24.83

3.13

−4.35

−15.43

1.95

0.148

Respiratory mortality

1.96

−2.99

6.39

6.78

−10.33

22.08

0.482

Neoplasm mortality

−0.96

−1.90

−0.17

−8.56

−17.05

−1.53

0.01***

All-cause medical mortality

−1.76

−6.51

−0.28

−4.48

−16.53

−0.70

0.038**

Philadelphia | 2015
Circulatory mortality

0.96

−13.22

9.47

0.86

−11.89

8.51

0.934

Respiratory mortality

−1.37

−5.10

1.43

−5.95

−22.21

6.22

0.336

Neoplasm mortality

−1.63

−2.73

−0.99

−17.17

−28.72

−10.39

< 0.001***

All-cause medical mortality

−1.97

−5.92

−0.50

−6.77

−20.29

−1.71

0.018**

New York | 2014
Circulatory mortality

−0.39

−25.30

19.57

−0.87

−56.70

43.86

0.802

Respiratory mortality

−3.00

−10.44

4.42

−26.77

−93.16

39.48

0.322

Neoplasm mortality

−1.03

−2.86

0.203

−34.46

−95.69

6.77

0.096*

All-cause medical mortality

−2.78

−10.65

−0.13

−18.11

−69.29

−0.86

0.04**

Boston | 2014
Circulatory mortality

−7.33

−18.72

2.50

−15

−38.31

5.12

0.144

Respiratory mortality

−0.67

−5.19

4.68

−6.07

−47.09

42.46

0.836

Neoplasm mortality

−1.35

−2.49

−0.55

−22.17

−40.93

9.06

0.004***

All-cause medical mortality

−1.39

−4.53

0.09

−8.85

−28.77

0.57

0.068*

* ≤0.10 ** ≤ 0.05 *** ≤ 0.01.
†
Percentage change of post-intervention mortality of Medicaid expansion city from synthetic control prediction.

FIGURE 11 | Average mortality rates among treated cities and synthetic control cities. These bar graphs represent the average mortality rate of the selected
Northeastern cities. Mortality rates before and after Medicaid expansion are illustrated along with the predicted average mortality rates if Medicaid expansion had not
occurred in said cities (derived by the generalized synthetic control model).
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Unlike Washington D.C. and Philadelphia, the 2006 Primary
Adult Care (PAC) program under the HealthChoice program
in Baltimore expanded coverage (prescription, primary care,
behavioral health) to childless adults at or below 116%
FPL (45). Accordingly, Medicaid expansion did moderately
expand Baltimore’s coverage criteria from baseline. Nevertheless,
Washington D.C. and Baltimore had the highest mortality
rates before Medicaid expansion; this inclines both cities to
larger observed effects. Medicaid expansion operated in the
context of Baltimore’s elevated mortality rates, higher poverty
rates, and large minority populations; these factors likely
promote greater Medicaid expansion effects. The aforementioned
factors suggest that Medicaid expansion might be most
efficacious in Washington D.C., Baltimore and Philadelphia.
The insurance rate models found significant increases in the
insured percentage of said cities as compared to those trends
predicted in the absence of Medicaid expansion. This provides
evidence that Medicaid expansion may have increased insurance
rates significantly.
Importantly, our findings diverge from state-wide analyses,
in that, the magnitude of Medicaid expansion impact was
larger in urban areas than in states as a whole. We attribute
this to multiple factors. First, the concentration of health
issues in urban areas may be more able to capture the health
effects of Medicaid expansion (21). Second, greater proximity
to medical care in urban environments, unlike rural areas,
suggests that financial access is a stronger variable in determining
healthcare access (46). With respect to Medicaid expansion
specifically, previous studies have shown that medical utilization
starkly increased in states after the introduction of Medicaid
expansion (28). Such observed increases in utilization along
with broader increases in physician supply and particularly
high densities of healthcare resources in large cities strongly
suggest that the increased access to care was achieved through
Medicaid coverage (28, 46). This further suggests that lesser
gains in urban coverage, as compared to rural populations,
can be potent in improving population health in urban
settings (47).
Certain limitations should be considered. Sensitivity
analyses indicated that yearly data were unable to derive
similarly statistically significant treatment effects as compared
to monthly data. This may be explained by differences in
granularity reducing study power, seasonal trends, etc.
Thus, it is likely that the yearly circulatory and respiratory
mortality data used are inadequate to capture treatment effects.
Otherwise, mortality is an extreme marker of population
health not fully representative of the total effects of Medicaid
expansion. Considering trend volatility, dissimilar baseline
mortality, different intervention sizes, and the fundamental
limitations in the GSC, lack of findings should not be
considered as precluding effects on certain types of mortality
(e.g., respiratory).
Like most other Medicaid expansion studies, this study
fundamentally compares mortality rates between non-ME
and Medicaid expansion states where these groups may
experience unique confounding influences given the ecological
nature of the data. For instance, city specific events related

TABLE 3 | Treatment effects on percentage of population insured in treated cities.
City | Intervention year

ATT

Washington D.C. | 2010

4.22%

0.28%

10.58%

Baltimore | 2014

3.23%

0.30%

10.56%

0.046**

Philadelphia | 2015

4.31 %

0.24%

6.66%

0.036**

New York | 2014
Boston | 2014

Lower 95% CI Higher 95% CI

p
0.048**

0.86%

−13.13%

9.75%

0.860

−12.54%

−16.91%

7.80%

0.618

** ≤ 0.05.

leading to appreciable mortality that can be avoided by early
diagnosis as potentially related to Medicaid expansion (41).
Neoplasm mortality reductions partly, but not fully, underlie
all-cause medical mortality reductions; unrelated reductions
may result from other causes that are amenable to increased
access; these may or may not have been captured separately
in our study.
Variations in the observed effect sizes between cities may be
related to distinct policy landscapes before Medicaid expansion.
Boston, for example, passed the MHCR in 2006 and this
already offered coverage to many near FLP. Indeed, baseline
mortality rates in Boston were lower than in other cities in
our study prior to Medicaid expansion. Further, extensive preMedicaid expansion insurance coverage and limited baseline
mortality suggest that ACA Medicaid expansion impacts be
minimal in Boston. Similarly, New York City had implemented
state-wide low-income coverage policies for non-elderly adults
prior to the formal expansion of Medicaid in 2014 (43).
Specifically, the 2001 Family Health Plus program was expanded
to 100% of FLP (43); this standing program may have reduced
the impact of Medicaid expansion in New York City. Such
characterization of these two policy landscapes is bolstered by
the results of the insurance rate analysis. Specifically, New
York and Boston did not observe significant gains in the
insured population as compared to their predicted trajectory
absent Medicaid expansion. Nevertheless, we do observe smaller
and statistically insignificant gains in the insured rate after
Medicaid Expansion; given the already high rates, we anticipate
that only minor gains in insurance rates would have been
possible, so that this limited magnitude may not achieve
statistical significance.
By contrast, the remaining cities resided in states where
Medicaid expansion resulted in a large expansion in their
public insurance eligibility criteria. Before its early expansion
of Medicaid in 2010, Washington D.C. had only adopted
narrow programs beyond the federal Medicaid requirements.
Washington D.C. not only expanded Medicaid early, but
the district set eligibility criteria to 210% FPL, which
makes this expansion the largest of any included city (44).
Similarly, Pennsylvania had heavily utilized waivers to create
several targeted programs but none of these programs were
broadly applicable to Medicaid expansion-eligible populations.
Philadelphia had similar mortality rates to Washington D.C.
but the extent of Medicaid expansion was less significant (i.e.,
138% FPL).
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given the unique treatment intensity and policy history
characterized above.
Significant reductions in multiple forms of urban mortality
were attributed to Medicaid expansion. The degree of effects was
seemingly related to baseline mortality rates, prior expansion
status, and the magnitude of Medicaid expansion. Our study
indicates that Medicaid expansion saved lives in the included
urban settings.

to police brutality, weather events, civil unrest, etc., may
be lay the ground for specific forms of medical-related
mortality via more diffuse factors (e.g., stress, slow medical
emergency response times). Nevertheless, these effects may
not strongly affect the sum magnitude of the observed
mortality and would likely only dampen observed degree
effects attributed to Medicaid expansion in the present study.
The use of only urban populations, numerous independent
relevant covariates, and the generalized synthetic control
method allow this study to limit the influence of observed
and unobserved confounding unlike most previous studies
of Medicaid expansion. Regardless, overfitting is a concern
in synthetic control models and while the GSC model does
improve upon overfitting issues found in the traditional
synthetic control methods via the use of semiparametric
estimation and cross-validation schema, the risk of overfitting
remains (25).
Unlike most literature, the county-level nature of this
analysis limits the number of individuals available for study.
As such, separate analyses of older sub-populations were
inviable given the limited size of such a sub-population
and the risk of stochastic variability biasing the model.
Nevertheless, the inclusion of younger and healthier populations
in the presented results more likely underestimates the
treatment effects of Medicaid expansion (28). Similarly,
the nature of the data utilized county-wide covariates, as
such analyses of mortality rates in subsets of particular
covariate categories (e.g., education-level) was unable to
be conducted. Further studies are required to determine
whether the observed effects of Medicaid expansion can
be generalized to other cities without Medicaid expansion.
To this point, each city’s results must be considered
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